
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ANT-301
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ANT-301 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 06, 2024
Lead Product(s) : ANT-301
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Allo-Asc
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Allo-Asc is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Epidermolysis Bullosa Dystrophica.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 15, 2021
Lead Product(s) : Allo-Asc
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Asc
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Asc is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Crohn's Fistula.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2020
Lead Product(s) : Asc
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Allo-Asc is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 29, 2020

Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers
Details : Allo-Asc is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 04, 2020

Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers
Details : Allo-Asc is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 27, 2018

Details : Allo-Asc is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 13, 2017

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Allo-Asc
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Allo-Asc is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Burns.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 02, 2015
Lead Product(s) : Allo-Asc
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers
Details : Allo-Asc is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 02, 2015

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Allo-Asc
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease
Details : Allo-Asc is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 20, 2015
Lead Product(s) : Allo-Asc
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All